Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1

Journal of Cell Biology

Volumn 146, Issue 4, 1999, Pages 881-892

  Martin, David C ^a   Fowlkes, John L ^b   Babic, Bojana ^a   Khokha, Rama ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Extracellular proteolysis; Insulin like growth factor II; Signal transduction; TIMP 1; Tumor suppression

Indexed keywords

MESSENGER RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; LIVER HYPERPLASIA; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; HYPERPLASIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; METALLOENDOPEPTIDASES; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0033598169     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.146.4.881     Document Type: Article

References (78)

1. Alexander, C.M., and Z. Werb. 1989. Proteinases and extracellular matrix remodeling. Curr. Opin. Cell Biol. 1:974-982.
2. Anand-Apte, B., M.S. Pepper, E. Voest, R. Montesano, B. Olsen, G. Murphy, S.S. Apte, and B. Zetter. 1997. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Opthalmol. Vis. Sci. 38:817-823.
3. Bae, M.H., M.J. Lee, S.K. Bae, O.H. Lee, Y.M. Lee, B.C. Park, and K.W. Kim. 1998. Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity. Cancer Lett. 128: 41-46.
4. Bates, P., R. Fisher, L. Ward, L. Richardson, D.J. Hill, and C.F. Graham. 1995. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer. 72:1189-1193.
5. Blobel, C.P. 1997. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell. 90:589-592.
6. Bozyczko-Coyne, D., M.A. Glickman, J.E. Pratner, B. McKenna, T. Conners, and C. Friedman. 1993. IGF-I supports the survival and/or differentiation of multiple types of central nervous system neurons. Ann. N. Y. Acad. Sci. 692: 311-313.
7. Casola, S., P. Ungaro, P.V. Pedone, D. Lazzaro, E. Fattori, G. Ciliberto, R. Zarrilli, C.B. Bruni, and A. Riccio. 1995. Loss of heterozygosity of imprinted genes in SV40t/T antigen-induced hepatocellular carcinomas. Oncogene. 11: 711-721.
8. Chan, J.M., M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens, and M. Pollak. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:563-566.
9. Chernausek, S.D., C.E. Smith, K.L. Duffin, W.H. Busby, G. Wright, and D.R. Clemmons. 1995. Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4. J. Biol. Chem. 270:11377-11382.
10. Christofori, G., P. Naik, and D. Hanahan. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369: 414-418.
11. Cohen, P., H.C. Graves, D.M. Peehl, M. Kamarei, L.C. Giudice, and R.G. Rosenfeld. 1992. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75:1046-1053.
12. Conover, C.A., and D.D. De Leon. 1994. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J. Biol. Chem. 269:7076-7080.
13. Conover, C.A., S.K. Durham, J. Zapf, F.R. Masiarz, and M.C. Kiefer. 1995. Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants. J. Biol. Chem. 270:4395-4400.
14. Dallas, S.L., K. Miyazono, T.M. Skerry, G.R. Mundy, and L.F. Bonewald. 1995. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J. Cell Biol. 131:539-549.
15. D'Armiento, J., T. DiColandrea, S.S. Dalal, Y. Okada, M.T. Huang, A.H. Conney, and K. Chada. 1995. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumori-genesis. Mol. Cell. Biol. 15:5732-5739.
16. Daughaday, W.H., and P. Rotwein. 1989. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10:68-91.
17. Davenport, M.L., J. Pucilowska, D.R. Clemmons, R. Lundbland, J.A. Spencer, and L.E. Underwood. 1991. Tissue-specific expression of tGFBP-3 protease activity during rat pregnancy. Endocrinology. 130:2505-2512.
18. De Leon, D.D., and Y. Asmerom. 1997. Quantification of insulin-like growth factor I (IGF-1) without interference by IGF-1 binding proteins. Endocrinology. 138:2199-2202.
19. DeCaprio, J.A., J.W. Ludlow, J. Frigge, J.Y. Shew, C.M. Huang, W.H. Lee, E. Marsilio, E. Paucha, and D.M. Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell. 54:275-283.
20. DeClerck, Y.E., N. Perez, H. Shimada, T.C. Boone, K.E. Langley, and S.M. Taylon. 1992. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:701-708.
21. Denhardt, D.T., B. Feng, D.R. Edwards, E.T. Cocuzzi, and U.M. Malyankar. 1993. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol. Ther. 59:329-341.
22. D'Errico, A., W.F. Grigioni, M. Fiorentino, P. Baccarini, E. Lamas, S. De Mitri, G. Gozzetti, A.M. Mancini, and C. Brechot. 1994. Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study. Pathol. Int. 44:131-137.
23. Dunn, S.E., M. Ehrlich, N.J. Sharp, K. Reiss, G. Solomon, R. Hawkins, R. Baserga, and J.C. Barerett. 1998. A dominant negative mutant of the insulin-like growth factor-I receplor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58:3353-3361.
24. Flaumenhaft, R., and D.B. Rifkin. 1991. Extracellular matrix regulation of growth factor and protease activity. Curr. Opin. Cell Biol. 3:817-823.
25. Fowlkes, J.L. 1997. Insulin-like growth-factor binding protein proteolysis: an emerging paradigm in insulin-like growth factor physiology. Trends Endocrinol. Metab. 8:299-306.
26. Fowlkes, J.L., J.J. Enghild, K. Suzuki, and H. Nagase. 1994a. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:25742-25746.
27. Fowlkes, J.L., K. Suzuki, H. Nagase, and K.M. Thrailkill. 1994h. Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology. 135:2810-2813.
28. Fowlkes, J.L., K.M. Thrailkill, D.M. Serra, and H. Nagase. 1997. Insulin-like growth factor binding protein (IGFBP) substrate zymography. A new tool to identify and characterize IGFBP-degrading proteinases. Endocrine. 7:33-36.
29. Gargosky, S.E., H.M. Pham, K.F. Wilson, F. Liu, L.C. Giudice, and R.G. Rosenfeld. 1992. Measurement and characterization of insulin-like growth factor binding protein-3 in human biological fluids: discrepancies between radioimmunoassay and ligand blotting. Endocrinology. 131:3051-3060.
30. Haddad, R., and W.A. Held. 1997. Genomic imprinting and IGF2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res. 57:4615-4623.
31. Hadsell, D.L., N.M. Greenberg, J.M. Fligger, C.R. Baumrucker, and J.M. Rosen. 1996. Targeted expression of des (1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology. 137:321-330.
32. Han, V.K., P.K. Lund, D.C. Lee, and A.J. D'Ercole. 1988. Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. J. Clin. Endocrinol. Metab. 66:422-429.
33. Hankinson, S.E., W.E. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer, and M. Pollak. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351: 1393-1396.
34. Harris, T.M., L.E. Rogler, and C.E. Regler. 1998. Reactivation of the maternally imprinted IGF2 allele in TGFalpha induced hepatocellular carcinomas in mice. Oncogene. 16:203-209.
35. Imai, Y., W.H. Busby, Jr., C.E. Smith, J.B. Clarke, A.J. Garmong, G.D. Horwitz, C. Rees, and D.R. Clemmons. 1998. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J. Clin. Invest. 100: 2596-2605.
36. Jones, J.I., and D.R. Clemmons. 1995. Insulin-like growth factors and their binding proteins: biologic actions. Endocr. Rev. 16:3-34.
37. Khokha, R. 1994. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of tissue inhibitor of metalloproteinase-1. J. Natl. Cancer Inst. 86:299-304.
38. Khokha, R., P. Waterhouse, S. Yagel, P.K. Lala, C. Overall, G. Norton, and D. Denhardt. 1989. Antisense RNA-induced reduction in murine TIMP levels confers oncogenecity on Swiss 3T3 cells. Science. 244:947-950.
39. Kimura, Y., H. Koga, N. Mugita, N. Fujita, H. Takeshima, T. Nishi, T. Yamashima, T.C. Saido, T. Yamasaki, K. Moritake, et al. 1998. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat. Med. 4:915-922.
40. Krüger, A., J.E. Fata, and R. Khokha. 1997. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood. 90:1993-2000.
41. Krüger, A., O.H. Sanchez-Sweatman, D.C. Martin, F.W. Orr, U. Rüther, and R. Khokha. 1998. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene. 16:2419-2423.
42. Lassarre, C., and M. Binoux. 1994. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology. 134:1254-1262.
43. Lassarre, C., C. Lalou, L. Perin, and M. Binoux. 1994. Protease-induced alteration of insulin-like growth factor binding protein-3 as detected by radioimmunoassay. Agreement with ligand blotting data. Growth Regul. 4:48-55.
44. Levi, E., R. Fridman, H.Q. Miao, Y.S. Ma, A. Yayon, and I. Vlodavsky. 1996. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA. 93:7069-7074.
45. Liotta, L.A., P.S. Steeg, and W.G. Stetler-Stevenson. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64: 327-336.
46. Liu, P., O. Terradillos, C.A. Renard, G. Feldmann, M.A. Buendia, and D. Bernuan. 1997. Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor-II. Hepatology. 25:874-883.
47. Martin, D.C., U. Rüther, O.H. Sanchez-Sweatman, F.W. Orr, and R. Khokha. 1996. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene. 13:569-576.
48. Martin, D.C., O.H. Sanchez-Sweatman, A.T.-V. Ho, D.S. Inderdeo, M.-S. Tsao, and R. Khokha. 1999. Transgenic TIMP-1 inhibits SV40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. 79:225-234.
49. Matrisian, L.M. 1992. The matrix-degrading metalloproteinases. Bioessays. 14: 455-463.
50. McCusker, R.H., W.H. Busby, M.H. Dehoff, C. Camacho-Hubner, and D.R. Clemmons. 1991. Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF-binding proteins. Endocrinology. 129:939-949.
51. Mignatti, P., and D.B. Rifkin. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:161-195.
52. Murphy, L.J., G.I. Bell, and H.G. Friesen. 1987. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology. 120:1279-1282.
53. Osborne, C.K., E.B. Coronado, L.J. Kitten, C.I. Arteaga, S.A. Fuqua, K. Ramasharma, M. Marshall, and C.H. Li. 1989. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-1 receptor. Mol. Endocrinol. 3:1701-1709.
54. Rees, C., D.R. Clemmons, G.D. Horvitz, J.B. Clarke, and W.H. Busby. 1998. A protease resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions. Endocrinology. 139:4182-4188.
55. Resnicoff, M., and R. Baserga. 1998. The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann. N.Y. Acad. Sci. 842:76-81.
56. Resnicoff, M., D. Abraham, W. Yutanawiboonchai, H.L. Rotman, and R. Rubin. 1995. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:2463-2469.
57. Rogler, C.E., D. Yang, L. Rossetti, J. Donohoe, E. Alt, C.J. Chang, R. Rosenfeld, K. Neely, and R. Hintz. 1994. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem. 269:13779-13784.
58. Rubin, R., and R. Baserga. 1995. Insulin-like growth factor I receptor. Its role in cell proliferation, apoptosis and tumorigenesis. Lab. Invest. 73:311-331.
59. Rüther, U., C. Woodroofe, E. Fattori, and G. Ciliberto. 1993. Inducible formation of liver tumors in transgenic mice. Oncogene. 8:87-93.
60. Schirmacher, P., W.A. Held, D. Yang, F.V. Chisari, Y. Rustum, and C.E. Rogler. 1992. Reactivation of insulin-like growth factor II during hepatocarcino-genesis in transgenic mice suggests a role in malignant growth. Cancer Res. 52:2549-2556.
61. Schoenle, E., J. Zapf, C Hauri, T. Steiner, and E.R. Froesch. 1985. Comparison of in vivo effects of insulin-like growth factors I and II and of growth hormone in hypophysectomized rats. Acta Endocrinol. 108:167-174.
62. Sell, C., M. Rubini, R. Rubin, J.P. Liu, A. Efstratiadis, and R. Baserga. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type I insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA. 90:11217-11221.
63. Shimisaki, S., and N. Ling. 1991. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Prog. Growth Factor Res. 3:243-266.
64. Sohda, T., Y. Oka, K. Iwata, J. Gunn, S. Kamimura, H. Shijo, M. Okumura, and K. Yun. 1997. Co-localization of insulin-like growth factor II and the proliferation marker MIB1 in hepatocellular carcinoma cells. J. Clin. Pathol. 50: 135-137.
65. Sympson, C.J., R.S. Talhouk, C.M. Alexander, J.R. Chin, S.M. Clift, M.J. Bissell, and Z. Werb. 1994. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. 125:681-693.
66. Sympson, C.J., M.J. Bissell, and Z. Werb. 1995. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin. Cancer Biol. 6:159-163.
67. Tan, T.H., J. Wallis, and A.J. Levine. 1986. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J. Virol. 59:574-583.
68. Tennant, M.K., J.B. Thrasher, P.A. Twomey, R.H. Drivdahl, R.S. Brinbaum, and S.R. Plymate. 1996. Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81:3774-3782.
69. Thrailkill, K.M., L.D. Quarles, H. Nagase, K. Suzuki, D.M. Serra, and J.L. Fowlkes. 1995. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology. 136:3527-3533.
70. Wang, M., Y.E. Liu, J. Greene, S. Sheng, A. Fuchs, E.M. Rosen, and Y.E. Shi. 1997. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase-4. Oncogene. 14: 2767-2774.
71. Werb, Z. 1997. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:439-442.
72. Werner, H., and D. LeRoith. 1996. The role of insulin-like growth factor system in human cancer. Adv. Cancer Res. 68:183-223.
73. Werner, H., and D. Le Roith. 1997. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit. Rev. Oncog. 8:71-92.
74. Whitelock, J.M., A.D. Murdoch, R.V. Iozzo, and P.A. Underwood. 1996. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271:10079-10086.
75. Wilson, C.L., K.J. Heppner, P.A. Laboski, B.L. Hogan, and M.L. Matrisian. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA. 94:1402-1407.
76. Witty, J.P., J.H. Wright, and L.M. Matrisian. 1995. Matrix metalloproteinases are expressed during ductal alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled mammary alveolar development. Mol. Biol. Cell. 6:1287-1303.
77. Wolf, E., A. Hoeflich, and H. Lahm. 1998. What is the function of IGF-II in postnatal life? Answers from transgenic mouse models. Growth Horm. IGF Res. 8:185-193.
78. Zhang, L., F. Kashanchi, Q. Zhan, S. Zhan, J.N. Brady, A.J. Fornace, P. Seth, and L.J. Helman. 1996. Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res. 56: 1367-1373.